Datar Cancer Genetics
Datar Cancer Genetics (DCG) offers a comprehensive suite of next-generation in vitro diagnostic (IVD) cancer tests. The tests support clinicians and patients across the entire cancer care journey from healthy/asymptomatic to therapy guidance and monitoring for refractory cancers. DCG tests are for the full range of solid organ tumours – and we have 3 US FDA Breakthrough Device designations for tests in prostate, breast and brain cancer.
We process test samples at our internationally accredited labs in Guildford, Surrey. DCG provides full support throughout the process, from supplying sample collection kits to delivering results within a few days.
Our multi-cancer tests use both tissue and liquid biopsies for:
- Familial Cancer Predisposition Testing: Identifies individuals with a genetic predisposition to developing cancer, allowing for early intervention and preventative measures
- Early Cancer Detection: Leverages our proprietary Circulating Tumour Cell (CTC) enrichment technology for the sensitive detection of solid tumours at an early stage
- Comprehensive Treatment Guidance: combines DCG’s proprietary CTC technology and multi-cancer NGS panels to bring clinically actionable recommendations for advanced / refractory / rare cancers
- Disease Monitoring: Enables continuous monitoring of disease status during and after treatment, allowing for timely detection of recurrence or treatment resistance
Visit https://uk.datarpgx.com/ for further details. For details on our peer-reviewed clinical and scientific published papers please visit https://uk.datarpgx.com/publications/.
